Oxford GlycoSciences Plc Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oxford GlycoSciences Plc

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jongmans who started this subject	8/22/2000 11:45:07 AM
From: nigel bates	Read Replies (1) of 469

Oxford GlycoSciences (LSE: OGS.L - news) Plc shares fell 12 percent in London on Tuesday. The company attributed the fall to a downgrade from equities analysts at UBS Warburg, which changed its recommendation to sell from buy based on concerns about a drug OGS is developing. The drug is designated OGT-918 and is in clinical testing for a rare metabolic disorder called Gaucher's disease, but a letter appearing in last week's issue of the Lancet medical journal questioned the safety and efficacy of the drug. OGS is best known in the industry for its protein analysis systems, intended to speed the study of gene function. OGS shares were trading at 1722.50 pence, down 12 percent, in London on Tuesday afternoon.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next